Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SS)
CNY 21.0
(0.92%)
CNY 21.0
(0.92%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -929.77 Million CNY | -8.24% |
| 2022 | -856.31 Million CNY | -24.41% |
| 2021 | -678.69 Million CNY | -17.94% |
| 2020 | -583.63 Million CNY | 34.13% |
| 2019 | -881.52 Million CNY | -737.47% |
| 2018 | -160.99 Million CNY | -16.69% |
| 2017 | -91.14 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q3 | -234.76 Million CNY | -20.17% |
| 2024 Q1 | -191.25 Million CNY | 44.08% |
| 2024 Q2 | -195.35 Million CNY | -2.15% |
| 2023 Q2 | -170.63 Million CNY | 28.13% |
| 2023 FY | - CNY | -8.24% |
| 2023 Q3 | -255.52 Million CNY | -49.75% |
| 2023 Q1 | -237.42 Million CNY | 9.29% |
| 2023 Q4 | -367.6 Million CNY | -43.86% |
| 2022 Q3 | -265.92 Million CNY | -32.84% |
| 2022 Q2 | -200.17 Million CNY | 8.07% |
| 2022 Q1 | -217.75 Million CNY | 13.01% |
| 2022 FY | - CNY | -24.41% |
| 2022 Q4 | -261.74 Million CNY | 1.57% |
| 2021 FY | - CNY | -17.94% |
| 2021 Q4 | -250.31 Million CNY | -48.86% |
| 2021 Q3 | -168.15 Million CNY | 8.51% |
| 2021 Q2 | -183.8 Million CNY | -17.87% |
| 2021 Q1 | -155.93 Million CNY | 12.73% |
| 2020 Q4 | -178.68 Million CNY | 5.08% |
| 2020 Q3 | -188.25 Million CNY | 0.0% |
| 2020 FY | - CNY | 34.13% |
| 2019 FY | - CNY | -737.47% |
| 2018 FY | - CNY | -16.69% |
| 2017 FY | - CNY | 0.0% |